Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDASIA Has Low Profile in Pharma Earnings Calls

This article was originally published in RPM Report

Executive Summary

In the wave of pharma earnings calls after the July 9 signing of the FDA Safety & Innovation Act, the good news is that the law did not appear to be a material event for most companies and investors. The lack of attention to the law by management teams and analysts is a quiet reaffirmation that this iteration of the user fee reauthorization went smoothly for industry and the regulatory agency.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS081040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel